Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 9:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 567 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Art Therapy Clear all
Completed Phase 2 Interventional

The Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3

NCT00000825
View directory record Official record
Conditions
HIV Infections
Interventions
Aldesleukin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 2, 2026, 9:26 PM EDT
Completed Phase 3 Interventional Results available

A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)

NCT01263015
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus I
Interventions
Dolutegravir, Atripla, Abacavir/Lamivudine, Abacavir/Lamivudine Placebo, Dolutegravir placebo, Atripla placebo
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
844 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
55
States / cities
Hobson City, Alabama • Little Rock, Arkansas • Bakersfield, California + 42 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Oct 2, 2026, 9:26 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Clinical Study of TUTI-16 in Asymptomatic HIV-1 Infected Subjects (THYMON-11001)

NCT01335191
View directory record Official record
Conditions
HIV Infections
Interventions
TUTI-16 (1.0 mg), Placebo
Biological · Other
Lead sponsor
Thymon, LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 15, 2013 · Synced Oct 2, 2026, 9:26 PM EDT
Completed Phase 3 Interventional

Next Generation Ingestible Sensors for Medication Adherence Measurement

NCT05592613
View directory record Official record
Conditions
HIV Infection, Adherence, Medication, Adherence, Treatment, Pre-Exposure Prophylaxis, Antiretroviral Therapy
Interventions
Next-generation Reader and ID-Cap System, Truvada for pre-exposure prophylaxis (PrEP), Biktarvy for antiretroviral therapy (ART)
Device · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 25, 2024 · Synced Oct 2, 2026, 9:26 PM EDT
Completed Not applicable Interventional

A Study of Thalidomide in HIV-Infected Patients Who Are Receiving HAART

NCT00002392
View directory record Official record
Conditions
HIV Infections
Interventions
Thalidomide
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 2, 2026, 9:26 PM EDT
Completed Phase 1 Interventional Results available

Evaluating the Safety, Tolerability, and Effect of a Human Monoclonal Antibody (VRC01) on Markers of HIV Persistence in HIV-Infected Adults Receiving Antiretroviral Therapy (ART)

NCT02411539
View directory record Official record
Conditions
HIV Infections
Interventions
VRC01, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
13
States / cities
San Diego, California • Aurora, Colorado • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 2, 2026, 9:26 PM EDT
Completed Phase 2 Interventional Results available

Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma

NCT00267865
View directory record Official record
Conditions
AIDS-Related-Primary Central Nervous System Lymphoma
Interventions
Methotrexate, Rituximab, Leucovorin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 1, 2020 · Synced Oct 2, 2026, 9:26 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Clinical Trial to Look at the Safety and Immune Responses of the RNA-based Vaccine BNT168 in Adults Living With or Without HIV

NCT07698600
View directory record Official record
Conditions
HIV -1 Infection
Interventions
BNT168, Placebo
Biological · Other
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years to 50 Years
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 2, 2026, 9:26 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Accelerated Radiation Therapy (ART) to the Breast and Nodal Stations

NCT02917421
View directory record Official record
Conditions
Breast Cancer
Interventions
Radiation
Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
19 Years to 99 Years · Female only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 2, 2026, 9:26 PM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate Effects of Vorinostat and HXTC on Persistent HIV-1 Infection in HIV-Infected Subjects Started on Antiretroviral Therapy (ART)

NCT03212989
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Vorinostat, HXTC
Drug · Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 64 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 12, 2023 · Synced Oct 2, 2026, 9:26 PM EDT
Completed Not applicable Interventional

Effect of Tenofovir Disoproxil Fumarate on Lipid Levels in HIV Infected Adults on Stable Anti-HIV Drug Therapy

NCT00109603
View directory record Official record
Conditions
HIV Infections, Dyslipidemia, Hyperlipidemia, Hypercholesterolemia, Hypertriglyceridemia
Interventions
Tenofovir disoproxil fumarate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
19
States / cities
Los Angeles, California • San Diego, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2012 · Synced Oct 2, 2026, 9:26 PM EDT
Completed Phase 1Phase 2 Interventional Results available

N-acetylcysteine to Reduce Oxidative Stress and Improve Endothelial Function in HIV-infected Older Adults

NCT01962961
View directory record Official record
Conditions
HIV, Endothelial Dysfunction, Oxidative Stress
Interventions
PharmaNAC (N-acetylcysteine), Matching placebo
Dietary Supplement
Lead sponsor
Indiana University
Other
Eligibility
50 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 8, 2016 · Synced Oct 2, 2026, 9:26 PM EDT
Completed Phase 2 Interventional Results available

A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir

NCT00950859
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK1349572 (Cohort I), GSK1349572 (Cohort II)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
12
States / cities
Phoenix, Arizona • Long Beach, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2015 · Synced Oct 2, 2026, 9:26 PM EDT
Recruiting Not applicable Interventional

SCOPE Analytic Treatment Interruption Protocol

NCT04359186
View directory record Official record
Conditions
HIV/AIDS
Interventions
Treatment Interruption Arm
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 2, 2026, 9:26 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Osteopathic Manipulative Treatment RCT and Computational Modeling for Head Injuries in Mixed Martial Artists

NCT06851234
View directory record Official record
Conditions
Head Injury Trauma
Interventions
osteopathic manipulative medicine, The sham light touch will be performed by an investigator not trained in bodywork or a first--year osteopathic medical student.
Procedure
Lead sponsor
New York Institute of Technology
Other
Eligibility
18 Years to 50 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Greenvale, New York
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Oct 2, 2026, 9:26 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Dipyridamole for Immune Activation in HIV

NCT02121756
View directory record Official record
Conditions
HIV Infection
Interventions
Dipyridamole, Placebo, then Dipyridamole
Drug
Lead sponsor
Sharon Riddler
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 11, 2019 · Synced Oct 2, 2026, 9:26 PM EDT
Completed Phase 2 Interventional Results available

Randomized, Placebo-Controlled Study of Leptin for the Treatment of HIV Lipodystrophy and Metabolic Syndrome

NCT00140244
View directory record Official record
Conditions
HAART-induced Lipodystrophy and Metabolic Syndrome
Interventions
r-metHuLeptin, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Oct 2, 2026, 9:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

China Adherence Through Technology Study

NCT01722552
View directory record Official record
Conditions
Medication Adherence
Interventions
adherence feedback, standard of care
Behavioral
Lead sponsor
Boston University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 21, 2017 · Synced Oct 2, 2026, 9:26 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

PET Imaging of Radiolabeled Anti-HIV-1 Envelope Monoclonal Antibody (VRC01)

NCT03729752
View directory record Official record
Conditions
HIV-1-infection
Interventions
[89]Zr-DFO-VRC-HIVMAB060-00-AB
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 2, 2026, 9:26 PM EDT
Terminated Phase 4 Interventional

Raltegravir (Isentress/MK-0518) and HIV-1 Infected CD4 Cells During Acute/Early HIV-1

NCT00781287
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
3-drug anti-HIV therapy, Raltegravir
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 12, 2013 · Synced Oct 2, 2026, 9:26 PM EDT
Completed Phase 1 Interventional

Safety of Recombinant HIV Vaccines in HIV Infected Young Adults on Stable Therapy

NCT00107549
View directory record Official record
Conditions
HIV Infections
Interventions
rMVA-HIV (env/gag [TBC-M358] + tat/rev/nef-RT [TBC-M335)]), rFPV-HIV (env/gag [TBC-F357] + tat/rev/nef-RT [TBC-F349])
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 24 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2009
U.S. locations
8
States / cities
Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 2, 2026, 9:26 PM EDT
Completed Not applicable Interventional

Physician Focused Intervention to Improve Adherence With HIV Antiretrovirals

NCT00870792
View directory record Official record
Conditions
HIV Infection, HIV Infections
Interventions
Adherence report
Behavioral
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 2, 2026, 9:26 PM EDT
Completed Not applicable Interventional

Improving Food Security and Nutrition to Promote ART Adherence in Latin America

NCT01191281
View directory record Official record
Conditions
Medication Adherence
Interventions
Diet/nutrition counsel+food aid, Dietary/nutrition counsel
Behavioral · Other
Lead sponsor
RAND
Other
Eligibility
18 Years to 65 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Oct 18, 2012 · Synced Oct 2, 2026, 9:26 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Switching From Stavudine or Zidovudine to Tenofovir DF in HIV-1 Infected Children

NCT00528957
View directory record Official record
Conditions
HIV Infections
Interventions
Tenofovir DF, Zidovudine, Stavudine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
2 Years to 15 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
6
States / cities
Los Angeles, California • Fort Lauderdale, Florida • Jacksonville, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2018 · Synced Oct 2, 2026, 9:26 PM EDT